Skye Bioscience, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Skye Bioscience, Inc. (SKYE) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $2.39 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-06.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2020-11-06
- Skye Bioscience, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-03-31 was -$1.27M, a 149.47% decline year-over-year.
- Skye Bioscience, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2019-03-31 was $2.56M, a 4.68% decline year-over-year.
- Skye Bioscience, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2018-03-31 was $2.69M, a 751.27% increase year-over-year.
- Skye Bioscience, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2017-03-31 was $315.45K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month |
|---|---|---|---|
| 2020-09-30 | $2.39M 10-Q · filed 2020-11-06 | ||
| 2020-06-30 | -$1.73M 10-Q · filed 2020-08-13 | ||
| 2020-03-31 | -$1.27M 10-Q · filed 2020-05-08 | ||
| 2019-09-30 | -$534.01K 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $954.45K 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $2.56M 10-Q · filed 2020-05-08 | ||
| 2018-09-30 | $798.56K 10-Q · filed 2019-11-14 | ||
| 2018-06-30 | $1.61M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $2.69M 10-Q · filed 2019-05-10 | ||
| 2017-09-30 | -$55.91K 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | $44.04K 10-Q · filed 2018-08-10 | ||
| 2017-03-31 | $315.45K 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |